The human genome encodes several hundred E3 ligases — enzymes that decide which proteins a cell destroys — but drug developers have so far harnessed only a small fraction of them. In a review published in the journal Molecular Cell, researchers at Karolinska Institutet and the University of Verona argue that the remaining E3 ligases could hold the key to the next generation of cancer drugs.
Molecular glue degraders are small molecules that hijack the cell's own protein-disposal machinery to eliminate disease-causing proteins, including ones long considered beyond the reach of conventional drugs. They work by forcing proximity between an E3 ligase and a target protein, marking the target for destruction. According to Karolinska Institutet, this is one of the fastest-moving areas in drug discovery today.
"The field has so far relied on only a handful of E3 ligases," said Andrä Brunner, co-first author of the review and a researcher at Karolinska Institutet. "We map the molecular mechanisms underlying targeted protein degradation and describe how hidden degrons can be exposed and exploited by the many ligases that remain unused. Expanding this repertoire could open new avenues for reaching challenging targets, particularly in hard-to-treat cancers."
Daniele Guardavaccaro and Angela Lauriola of the University of Verona, also co-authors, noted in the review that knowledge of the interaction interfaces induced by molecular glues — the surfaces that allow an E3 ligase to engage its target — is still limited, except for a few well-characterised ligases. "Consequently, the field has thus far relied on only a small number of ligases for drug discovery and development," they said.
The review also outlines a framework for collaboration between the two groups. "Much of what we describe as untapped is exactly what we are now focusing on. We are working to identify the E3 ligases that could form the basis of the next generation of targeted protein degraders," said Olle Sangfelt at the Department of Cell and Molecular Biology, Karolinska Institutet.
The collaboration, titled "Exploiting the Ubiquitin System to Target the 'Undruggable' Cancer Proteome," is funded by a Swedish Research Council Project Grant under the Italy–Sweden programme.
For university students studying biochemistry, molecular biology, or drug discovery, the research highlights a fundamental shift in how scientists think about drugging the proteome. Many cancer-driving proteins lack the deep pockets that conventional small-molecule drugs need to bind to, making them "undruggable." Molecular glue degraders bypass that requirement entirely by co-opting the cell's own tagging system. If the approach succeeds in expanding the range of usable E3 ligases, it could eventually lead to treatments for cancers that currently have few therapeutic options.
Publication: Beneath the surface: Hidden degrons and untapped ligases for molecular glue degrader discovery. Brunner A, Lauriola A, Guardavaccaro D, Sangfelt O. Molecular Cell, 19 November 2026.